DOCetaxel With Or Without Radiation Therapy For Resectable Oesophageal Adenocarcinoma Based On Early PET Response To Induction Chemotherapy (DOCTOR).
Funder
National Health and Medical Research Council
Funding Amount
$1,024,738.00
Summary
Oesophageal cancer continues to have poor survival despite surgery. Patients responding to pre-operative chemotherapy have better survival than those who do not. This study proposes using early FDG-PET scan to identify patients not responding to standard chemotherapy. This will permit the timely change of therapy to alternative regimens with a newer agent with or without radiotherapy, aiming to improve outcomes. This represents a paradigm shift in the management of oesophageal cancer.
Exploiting Genetic Analysis To Predict Response And To Discover Novel Molecular Targeted Therapies For Rectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$83,871.00
Summary
Bowel cancer is a significant health burden in Australia. Currently it is difficult to predict which bowel cancer will shrink with standard therapy (chemoradiotherapy). Similarly, patients whose cancer remain the same or increase in size during treatment, there are no other new options available to them. In this research, I intend to find a model that could predict patient’s treatment pathway and identify alternative therapy for patients who did not respond to standard therapy.
Molecular Determinants Of Risk, Progression And Treatment Response In Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$15,161,573.00
Summary
The investigators, all associated with the Melanoma Institute Australia, have recruited numerous people and biospecimens in order to study the causes, subtypes and treatment strategies in melanoma. The team aims to develop a scientific basis for improved 1) management of individuals at high risk of melanoma development and progression, and 2) treatment of patients with early and disseminated melanoma, thereby contributing to improved prospects of successfully treating this dangerous cancer.
Deciphering Tumour Heterogeneity Of Breast Cancer Metastases Using Barcoded Patient Derived Xenografts
Funder
National Health and Medical Research Council
Funding Amount
$583,161.00
Summary
Breast cancer mortality is largely due to metastases that seed from the primary tumour. Breast tumours are known to contain a heterogeneous mix of cells, but the precise way that cells are selected for tumour growth and metastasis (as well as their response to systemic therapy) is not well understood. In this study we will use patient samples and cellular ‘barcoding’ to track the destiny of every single clone throughout disease progression and study the effect of various therapies on metastasis.
Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy In High Risk Cutaneous Squamous Cell Carcinoma Of The Head And Neck
Funder
National Health and Medical Research Council
Funding Amount
$252,000.00
Summary
Squamous cell carcinoma of the skin is one of the most common cancers affecting Australians. The majority are readily cured with simple local therapy, such as surgery. However some patients develop advanced disease requiring surgery and post-operative radiotherapy. Despite this, some patients do not achieve cure. This study aims to improve cure rates for these patients by comparing post-operative radiotherapy (control arm) to post-operative chemo-radiotherapy(experimental arm).
Randomised Phase II Trial Of Neoadjuvant Chemotherapy +/- Concurrent Aromatase Inhibitor Endocrine Therapy To Down-stage Large Oestrogen Receptor Positive Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$2,302,496.00
Summary
Women diagnosed with large oestrogen receptor positive breast cancer are often treated with chemotherapy before surgery to reduce the size of the cancer, while treatment to lower oestrogen levels is given after surgery. This trial is studying if combining chemotherapy with oestrogen lowering treatment before surgery will better shrink the cancer which can improve the surgery options.
The Australian Centre For Translational Breast Cancer Research: From Discovery To Better Health Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$2,619,075.00
Summary
TransBCR will implement a collaborative multidisciplinary research program to help fast track the clinical translation of promising laboratory discoveries in breast cancer. To overcome existing roadblocks, we will carry out early phase clinical trials of novel anti-breast cancer drugs linked to suitable diagnostic tests that help select the right therapy for individual cancer patients. Our goal is to help inform the swift delivery of cost-effective personalised medicine in breast cancer.
Detection of infrared-biomarkers for the diagnosis and treatment of canine neoplasia. This research hopes to discover infrared-biomarkers for canine cancers using synchrotron infrared and laser light. Many dog cancers are similar to human cancers so cancerous tissues and cells from dogs make excellent models for human cancer research. This project will provide new insights and technological approaches to cancer diagnosis and treatment.
EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers. Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “p ....EGFR-directed radioimmunotherapy combined with chemotherapy and DNA repair inhibition: development towards clinical application for aggressive cancers. Pancreatic ductal adenocarcinoma (PDAC) and triple negative breast cancer (TNBC) are aggressive diseases which lack effective therapies in clinical use. A novel and curative therapy was developed against PDAC and TNBC which involves targeted radiotherapy combined with chemotherapy and DNA damage response inhibition. This project will develop a “preclinical data package” comprising a biological rationale and preclinical evidence of safety and efficacy that together would justify an early phase clinical trial. This package includes the choice of formulations, mechanism of action and safety studies. This development will have an immediate impact for PDAC and TNBC patients and a future impact on other EGFR-positive cancers.Read moreRead less